Global EditionPremium world briefings with timeline, impact, and future-watch analysis.
Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
HealthNPR Health08 Aug, 07:00 pmAtlasHour
Health

Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development. But Kalshi and Polymarket say they provide valuable information to patients.

Source-linkedAtlasHour DeskNPR Health08 Aug, 07:00 pm

What happened

Researchers warn betting on clinical trials could incentivize insider trading and interfere with drug development.

Why it matters

AtlasHour context: this story may affect public policy, global affairs, business confidence, technology direction, energy security, or civic life.

Global context

The story is being tracked through Global Markets.

Who is affected

Global Markets

What to watch next

Readers should watch official responses, local reaction, source updates, and whether the story changes the next decision cycle.

Read the original source
Why It Matters

The consequence layer

AtlasHour context: this story may affect public policy, global affairs, business confidence, technology direction, energy security, or civic life.

Watch Next

What To Watch Next

Key Facts

Three facts to keep in view

1Source

NPR Health

1 min readRead time

Designed for a concise world-news brief.

1Context tags

Used for editorial story mapping and source context.

Read Next

Related Stories

AtlasHour updates articles as new verified information becomes available. Corrections and source context can be sent to the newsroom.